These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8106650)

  • 21. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moclobemide versus fluoxetine for double depression: a randomized double-blind study.
    Duarte A; Mikkelsen H; Delini-Stula A
    J Psychiatr Res; 1996; 30(6):453-8. PubMed ID: 9023788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.
    Braconnier A; Le Coent R; Cohen D;
    J Am Acad Child Adolesc Psychiatry; 2003 Jan; 42(1):22-9. PubMed ID: 12500073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression].
    Möslinger-Gehmayr R; Zaninelli R; Contu A; Oberhoff C; Gutschow K; Schindler AE; Staab HJ
    Zentralbl Gynakol; 2000; 122(4):195-202. PubMed ID: 10795116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
    Chouinard G; Saxena B; Bélanger MC; Ravindran A; Bakish D; Beauclair L; Morris P; Vasavan Nair NP; Manchanda R; Reesal R; Remick R; O'Neill MC
    J Affect Disord; 1999 Jul; 54(1-2):39-48. PubMed ID: 10403145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients.
    Cassano GB; Puca F; Scapicchio PL; Trabucchi M;
    J Clin Psychiatry; 2002 May; 63(5):396-402. PubMed ID: 12019663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
    Baldwin DS; Hawley CJ; Mellors K;
    J Psychopharmacol; 2001 Sep; 15(3):161-5. PubMed ID: 11565622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique.
    Bordet R; Thomas P; Dupuis B
    Am J Psychiatry; 1998 Oct; 155(10):1346-51. PubMed ID: 9766765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders.
    Manna V; Martucci N; Agnoli A
    Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():81-8. PubMed ID: 2644342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients.
    Gülseren L; Gülseren S; Hekimsoy Z; Mete L
    Arch Med Res; 2005; 36(2):159-65. PubMed ID: 15847950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study.
    Cassano GB; Jori MC;
    Int Clin Psychopharmacol; 2002 Jan; 17(1):27-32. PubMed ID: 11800503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, multicentre study of paroxetine and maprotiline in major depression.
    Schnyder U; Koller-Leiser A
    Can J Psychiatry; 1996 May; 41(4):239-44. PubMed ID: 8726790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J; Möller HJ; Burrows GD; Montenegro RM
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
    Aberg-Wistedt A; Agren H; Ekselius L; Bengtsson F; Akerblad AC
    J Clin Psychopharmacol; 2000 Dec; 20(6):645-52. PubMed ID: 11106136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.
    Guelfi JD; Ansseau M; Corruble E; Samuelian JC; Tonelli I; Tournoux A; Plétan Y
    Int Clin Psychopharmacol; 1998 May; 13(3):121-8. PubMed ID: 9690979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.
    Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD
    Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.